Revenue surge masks margin miss; HFC-32 execution key

Delivered ₹230.5 Cr, 36.6% YoY; matches claim

Gross profit INR75 Cr vs INR66 Cr YoY (13% up), but margin 32.5% vs 39% YoY; realization-driven mix correct

Prior guidance 21-22% FY27; new guidance 16% avg is 25% cut; H2 margin dependent on HFC-32 commissioning & cost moderation not yet proven

H1 delivered ₹418 Cr vs ₹345 Cr H1 FY26 (21.1% YoY); matches, but reveals Q1 weakness dragging H1 average

H1 FY27 PAT INR36 Cr vs H1 FY26 INR36 Cr (0% growth); concerning given 21% revenue growth

Prior FY27 guidance 30% growth → Revised to 35%-40%; driven by HFC-32 pre-contract demand & solar DHF surge. YoY growth in Q2 at 36.6% sits within new range, validating upside.

Prior FY27 guidance 21-22% blended → Revised to 16% average; margin compression from new product ramp (lower pricing in approval stage), HF realization mix, and 45-day cost pass-through lag.

Prior FY28 guidance ~60%+ growth → Revised to 55%-60% growth; capped by new product ramp uncertainty and R-32 volume assumptions (expecting 15,000-16,000 MT FY28, but current MOU only 5,000 MT unconverted).

New HF plant planned to support HFC-32 and R-32 demand (~13,000-15,000 MT HF consumption from projects). Total capex ₹70-80 Cr FY27 remaining + ₹250 Cr minimum FY28.

90% work complete by Sep 26; ₹360 Cr committed (90% of total). Q2 utilization 20%, Q3 95%, FY28+ 90-100%. Commercial production starts Q3.

Expect 15%-17% H2 (not 16%-19% as initially implied). Full-year 16% average due to new products and cost recovery lag. Margins normalize in FY28 to 24%-26% once HFC-32 scales.

FY27: 2,000-3,000 MT. FY28: 3,000-4,000 MT per quarter. Contracted at ~$7, spot $6.8-$7. Pricing moderates to $6.5-$7.5 if costs normalize and capacity online.

85%-87% from realization/mix (higher product pricing), 12%-15% from volume growth. HF capacity at 78% H1 utilization, 1/3 solar grade.

New products at lower margin in approval stage. Absolute margin intact, % margin down due to higher realization mix. New product contribution to increase in H2 significantly, with margin expansion.

Quarterly or monthly weighted avg pricing. 30-day lag typically. Sulphur +5x YoY (INR25/kg Oct 25 → INR120/kg Sep 26). Company passes on with lag, benefits in subsequent months.

Fluorospar bulk procurement due to geopolitical risk (3 months → 6-7 months). Creditors increased ₹50 Cr (offset). Temporary measure. Normal inventory in 1-2 quarters post-stabilization. September major revenue month (70% receivable collected Oct).

Trade market commercial production Dec 2026. OEM segment Jan 2027. Customer qualification ongoing; 2-3 months for approval. Some customers already qualified. MOU (5,000 MT) expected to convert to contract before FY27 year-end.

Currently favoring India (US antidumping duties on China in refrigerant gases benefit Indian makers). Too early to comment on future; depends on election outcomes and leadership changes.

30,000 MT total AHF (2 plants × 15 MT each); post-debottleneck ~31,000-32,000 MT. Solar: 12,000 MT (increasing to 12,500). R-32: ~13,000-15,000 MT future. Balance (~6,000-8,000 MT) for surface treatment & pharma. New HF plant planned for R-32/HFC demand.

Q2 at 36.6% YoY within new range. H1 only 21% YoY (dragged by weak Q1), so H2 must be ~45%+ to hit 35%-40% full-year. Conditional on HFC-32 ramp & new product demand.

Assumes HFC-32 full-year utilization + R-32 volumes 15,000-16,000 MT + solar DHF continued ramp. R-32 MOU conversion & commercial scaling key; FY28 growth lower than original 60%+ implies prudence or execution risk.

Q2 margin miss (implied EBITDA ~15-16% vs 20%+) suggests H1 average well below target. H2 guided 15%-17% expects recovery from new products scaling & cost moderation. Unproven.

Assumes HFC-32 commercialization, full-year production, new product margin expansion (from approval stage to normal). New product contribution to grow materially in H2 FY27. Dependent on execution.

₹360 Cr already committed for HFC-32; balance ₹30-40 Cr for debottleneck & ₹30-40 Cr for new HF capacity to support HFC-32 & R-32 HF demand.

Plan to expand AHF from 30k to 45k MT (15k new) & solar DHF from 25k to 50k MT (25k new). Capex amount & timing to be announced; depends on demand validation from H2 FY27.

Q2 OPM 11.8% vs prior guidance 16%-19%; EBITDA margin guidance cut 21-22% → 16% FY27. New product commercialization starting Dec with lower pricing in approval stage. Recovery contingent on volume scaling & cost moderation.

₹360 Cr capex 90% complete by Sep 26; commissioning targeted Q3 FY27 (Nov-Dec 2026). Binary catalyst: if delayed or utilization falls short of 95% Q3 target, H2 revenue guidance (35%-40% FY27) & margin recovery (15%-17% H2) both at risk.

Sulphur price +5x YoY (INR25/kg Oct 25 → INR120/kg Sep 26). Cost pass-through has 30-45 day lag (45 days for solar grade, quarterly/monthly for other segments). If raw material costs spike again, margins compressed for 1-2 months before customer pricing adjusts.

Fluorospar inventory increased ₹50 Cr (3 months → 6-7 months) due to West Asia geopolitical risk & container availability constraints. Working capital days rose 91 → 104 (+13 days). Offset by ₹50 Cr payables increase, but still a temporary cash-flow impact.

FY27 R-32 volumes expected 2,000-3,000 MT (low relative to HFC-32 demand); MOU for 5,000 MT pending contract conversion by FY27 year-end. Pricing contracted at ~$7/kg, spot $6.8-$7; if Chinese capacity comes online (40,000 MT domestic Indian MDC capacity, demand ~400 MT), R-32 pricing could compress to $6-6.5. FY28 volume assumption 15,000-16,000 MT assumes aggressive ramp-up from MOU conversion.

2-3 new fluorinated chemical products (specialty applications: electronics, agro, pharma, aerospace, EVs) launched in Q2-Q3 FY27. Currently in approval/pilot stage with lower margin pricing to penetrate market. Commercial production starts Dec 2026 (trade market), Jan 2027 (OEM segment). Customer qualification ongoing; 2-3 months for approval & samples. Risk: approval delays, customer qualification failures, or inability to scale to normal margins.